ICOTYDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Icotyde, and when can generic versions of Icotyde launch?
Icotyde is a drug marketed by Janssen Biotech and is included in one NDA. There are three patents protecting this drug.
This drug has eighty-two patent family members in thirty-three countries.
The generic ingredient in ICOTYDE is icotrokinra hydrochloride. One supplier is listed for this compound. Additional details are available on the icotrokinra hydrochloride profile page.
DrugPatentWatch® Generic Entry Outlook for Icotyde
Icotyde will be eligible for patent challenges on March 17, 2030. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be July 12, 2039. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
US Patents and Regulatory Information for ICOTYDE
ICOTYDE is protected by three US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ICOTYDE is ⤷ Start Trial.
This potential generic entry date is based on patent 12,552,836.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Biotech | ICOTYDE | icotrokinra hydrochloride | TABLET;ORAL | 220149-001 | Mar 17, 2026 | RX | Yes | Yes | 11,939,361 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Janssen Biotech | ICOTYDE | icotrokinra hydrochloride | TABLET;ORAL | 220149-001 | Mar 17, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Janssen Biotech | ICOTYDE | icotrokinra hydrochloride | TABLET;ORAL | 220149-001 | Mar 17, 2026 | RX | Yes | Yes | 11,845,808 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Janssen Biotech | ICOTYDE | icotrokinra hydrochloride | TABLET;ORAL | 220149-001 | Mar 17, 2026 | RX | Yes | Yes | 12,552,836 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ICOTYDE
When does loss-of-exclusivity occur for ICOTYDE?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Argentina
Patent: 4538
Estimated Expiration: ⤷ Start Trial
Patent: 9389
Estimated Expiration: ⤷ Start Trial
Australia
Patent: 20311395
Estimated Expiration: ⤷ Start Trial
Brazil
Patent: 2022000328
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 04418
Estimated Expiration: ⤷ Start Trial
Patent: 46390
Estimated Expiration: ⤷ Start Trial
China
Patent: 4341161
Estimated Expiration: ⤷ Start Trial
Patent: 6082455
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 20883
Estimated Expiration: ⤷ Start Trial
Patent: 97105
Estimated Expiration: ⤷ Start Trial
Israel
Patent: 9628
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 34382
Estimated Expiration: ⤷ Start Trial
Patent: 70605
Estimated Expiration: ⤷ Start Trial
Patent: 21530477
Estimated Expiration: ⤷ Start Trial
Patent: 22540154
Estimated Expiration: ⤷ Start Trial
Patent: 24147551
Estimated Expiration: ⤷ Start Trial
Mexico
Patent: 22000397
Estimated Expiration: ⤷ Start Trial
South Korea
Patent: 220044277
Estimated Expiration: ⤷ Start Trial
Taiwan
Patent: 2019948
Estimated Expiration: ⤷ Start Trial
Patent: 2116793
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering ICOTYDE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 121070 | ⤷ Start Trial | |
| Australia | 2021207653 | ⤷ Start Trial | |
| Brazil | 112022013957 | ⤷ Start Trial | |
| Canada | 3167751 | ⤷ Start Trial | |
| Chile | 2022001893 | ⤷ Start Trial | |
| Chile | 2024004039 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch